SOLVSolventum

•Data Privacy, Emerging Technology and Cybersecurity Laws - Because Solventum is a business with a significant global footprint, compliance with evolving regulations and standards in data privacy, emerging technologies, and cybersecurity may result in increased costs, compliance challenges and the threat of increased regulatory enforcement activity. Solventum’s business relies on the secure electronic transmission, storage and hosting of sensitive information, including personal information, protected health information, financial information, intellectual property and other sensitive information related to our customers and workforce. Solventum is required to comply with increasingly complex and changing legal and regulatory requirements that govern the collection, use, storage, security, transfer, disclosure and other processing of personal data data, including for the development and use of AI, in the U.S. and in other countries, including, countries. Examples of those laws include, but are not limited to, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), 1996, as amended, amended by the Health Information Technology for Economic and Clinical Health Act of 2009, 2009 (collectively, HIPAA), various U.S. state consumer privacy laws that have become effective recently, the California Consumer Privacy Act (“CCPA”) and other similar state laws in the U.S., the European Union’s Global EU General Data Protection Regulation (“GDPR”), (Regulation (EU) 2016/679 (GDPR) and the U.K.’s Data Protection Act 2018 and General Data Protection Regulation, United Kingdom's version of the same, the Lei Gerai de Proteção de Dados Pessoias (Brazil LGPD), China’s Personal Information Protection Law, Law (PIPL), PRC Cybersecurity Law and Personal Data Cross Border Transfer Rule, the European Union's Artificial Intelligence Act and various other country-specific requirements at the state and federal level around the world. In addition, privacy laws and regulations are becoming stricter and may potentially impose additional requirements on Solventum’s business, and certain jurisdictions have implemented data localization laws which can be costly and operationally difficult to satisfy. Similarly, the legal and regulatory landscape surrounding AI is rapidly evolving and uncertain and includes an increasingly large amount of complex, stringent, and inconsistent global regulations, including with regard to certification requirements in many of the countries in which Solventum's customers are located. Solventum cannot be sure how these laws and regulations will be interpreted, enforced enforced, or applied to its operations. operations, products and services. In addition to the risks associated with enforcement activities and potential contractual liabilities, Solventum’s ongoing efforts to comply with evolving laws and regulations may be costly and require ongoing modifications or limitations to its products, services, policies, procedures and systems. If Solventum or third parties are unable to effectively manage the use of AI or other emerging technologies by employees and third party providers, Solventum or third parties may fail to adequately safeguard confidential personal data, or if such information or data are wrongfully used by Solventum or third parties or disclosed to unauthorized persons or entities, such an event could result in a material adverse effect on its business, results of operations, financial condition and cash flows.

Because litigation is subject to inherent uncertainties, and unfavorable rulings or developments could occur, the Company may ultimately incur charges substantially in excess of presently recorded liabilities, including with respect to matters for which no accruals are currently recorded because losses are not currently probable and reasonably estimable. Many of the matters described herein are at varying stages, seek an indeterminate amount of damages or seek damages in amounts that the Company believes are not indicative of the ultimate losses that may be incurred. It is not uncommon for claims to be resolved over many years. As a matter progresses, the Company may receive information, through plaintiff demands, through discovery, in the form of reports of purported experts, or in the context of settlement or mediation discussions that purport to quantify an amount of alleged damages, but with which the Company may not agree. Such information may or may not lead the Company to determine that it is able to make a reasonable estimate as to a probable loss or range of loss in connection with a matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in future changes to determinations of probable and reasonably estimable losses in other matters.

Year ended December 31, (Dollars in millions) (Millions) 2025 2024 2025 vs 2024 change Segment Operating Income MedSurg $ 810 $ 887 (8.6)% Dental Solutions 346 350 (1.1) Health Information Systems 496 431 15.0 Purification and Filtration 96 74 29.7 All Other 42 30 40.0 Corporate and Unallocated 390 (736) 153.0 Total Company $ 2,181 $ 1,036 110.5% Year ended December 31, (Millions) 2024 2023 2024 vs 2023 change Segment Operating Income MedSurg $ 887 $ 1,107 (19.9)% Dental Solutions 350 442 (20.8) Health Information Systems 431 423 1.9 Purification and Filtration 94 162 (42.0) 74 111 (33.3) All Other 30 51 (41.2) Corporate and Unallocated (726) (736) (442) 64.3 66.5 Total Company $ 1,036 $ 1,692 (38.8)% Year ended December 31, (Dollars in millions) 2023 2022 2023 vs 2022 change Segment Operating Income MedSurg $ 1,107 $ 1,061 4.3% Dental Solutions 442 437 1.1 Health Information Systems 423 359 17.8 Purification and Filtration 162 177 (8.5) Corporate and Unallocated (442) (341) 29.6 Total Company $ 1,692 $ 1,693 (0.1)%

Income taxes: Prior to the Spin-Off, the Company was included in the consolidated U.S. federal, state, and foreign income tax returns of 3M, where applicable, through April 1, 2024. The Company's income tax provision for the periods 2022, 2023 and the first quarter of 2024 was prepared using the separate return method. The calculation of income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations. As a result, transactions included in the consolidated financial statements of 3M may not be included in the Company's consolidated financial statements. Similarly, the tax treatment of certain items reflected in the Company's consolidated financial statements may not be reflected in the consolidated financial statements and tax returns of 3M. Therefore, items such as net operating losses, credit carryforwards, and valuation allowances may exist in the Company's standalone financial statements that may or may not exist in 3M’s consolidated financial statements. After the Spin-Off, the Company has filed tax returns on its own behalf, and its income tax provision was prepared on a standalone basis. As a result, its deferred taxes and effective tax rate for 2025 may differ from those in the historical periods prior to Spin-Off.